A Phase 3, Multicenter, Randomized, Open-label, Performance Study With Self-administered Subcutaneous Rocatinlimab (AMG 451) in Adolescent and Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Outpost)
A Phase 3, Multicenter, Randomized, Open-label, Performance Study With Self-administered Subcutaneous Rocatinlimab (AMG 451) in Adolescent and Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Outpost)
The primary objective of this study is to assess successful self-administration of rocatinlimab subcutaneously using devices for injection.
Inclusion Criteria:
Exclusion Criteria:
Treatment with a biological product within 12 weeks or 5 half-lives, whichever is longer, prior to day 1 pre-randomization.
Treatment with any of the following medications or therapies within 5 half-lives prior to day 1 pre-randomization:
Treatment with any of the following medications or therapies within 1 week before day 1 pre-randomization:
Sakai-shi, Osaka 593-8324, Japan
Minato-ku, Tokyo 108-0014, Japan
Shinjuku-ku, Tokyo 160-8582, Japan
Ansan-si, Gyeonggi-do, 15355, South Korea
Suwon-si, Gyeonggi-do, 16499, South Korea